Rever3mAb is the most advanced antibody program in Takis pipeline.

Humanized Antibodies vs a membrane Tyrosine kinase

  • Validated target in Oncology
  • Generated by DNA electroporation technology

Where we are:

  • Preclinical studies in progress
  • Companion kit under development

Preferred Cancer Targets

  • melanoma
  • lung

Follow Us on Linkedin

Takis is a biotech dedicated to cancer research. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity.